A Multicenter Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer

Trial Profile

A Multicenter Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 30 Nov 2017

At a glance

  • Drugs Lurbinectedin (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Sponsors PharmaMar
  • Most Recent Events

    • 27 Nov 2017 Status changed from recruiting to active, no longer recruiting.
    • 02 Jun 2017 Results from this and one other study, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 19 May 2017 According to a PharmaMar media release, data from this trial will be presented at the 53rd Congress of the American Society of Clinical Oncology (ASCO) 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top